Press "Enter" to skip to content

FDA approves first biosimilar to Roche cancer drug Rituxan

Celltrion Inc’s Truxima on Wednesday became the first biosimilar to Roche Holding AG’s $7-billion-per-year cancer drug Rituxan to be approved in the United States to treat non-Hodgkin’s lymphoma.

Original source:

Also Read:   Top Kansas court rules state constitution protects abortion rights